This is few months old but here is our initial characterization of potent Nav1.8 inhibitors VX-150 and VX-548 (now called suzetrigine or Journavx). We found unusual "reverse" use-dependence that seems shared among Nav1.8-specific inhibitors molpharm.aspetjournals.org/article/S002...
State-Dependent Inhibition of Nav1.8 Sodium Channels by VX-150 and VX-548
Nav1.8 sodium channels (Nav1.8) are an attractive therapeutic target for pain because
they are prominent in primary pain-sensing neurons with little expression in most
other kinds of neurons. Recently...
molpharm.aspetjournals.org
March 31, 2025 at 9:47 PM
This is few months old but here is our initial characterization of potent Nav1.8 inhibitors VX-150 and VX-548 (now called suzetrigine or Journavx). We found unusual "reverse" use-dependence that seems shared among Nav1.8-specific inhibitors molpharm.aspetjournals.org/article/S002...